Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials
Publication date
2025-03
Authors
de Vries, Sieta T.
Pena, Michelle J.
Tye, Sok Cin
Peters, S. A E
van Raalte, Daniël H.
Arnott, Clare
Voors, Adriaan A.
Mol, Peter G.M.
Denig, Petra
Heerspink, Hiddo J.L.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Aims/hypothesis: Our aim was to assess sex differences in the efficacy of angiotensin receptor blockers (i.e. losartan and irbesartan) on kidney and cardiovascular outcomes in individuals with type 2 diabetes and diabetic kidney disease. Methods: Data from the Angiotensin II Antagonist Losartan Study (RENAAL) and Irbesartan type II Diabetic Nephropathy Trial (IDNT) were used. The kidney outcome was time to first event of end-stage kidney disease or doubling of serum creatinine. The cardiovascular outcome was time to first event of a composite of stroke, myocardial infarction, cardiovascular death or hospitalisation for heart failure. Sex differences were assessed by a sex × treatment interaction term in Cox proportional hazards models. Results: Included were 1737 male participants and 924 female participants. The beneficial effect of angiotensin receptor blockers on the kidney outcome was similar between male and female participants (HR in male participants 0.72 [95% CI 0.59, 0.86] vs HR in female participants 0.86 [95% CI 0.69, 1.06]; sex × treatment interaction HR 1.19 [95% CI 0.89, 1.59]). For the cardiovascular outcome, angiotensin receptor blockers lowered the risk in male but not in female participants (HR in male participants 0.81 [95% CI 0.69, 0.95] vs HR in female participants 1.11 [95% CI 0.88, 1.40]; sex × treatment interaction HR 1.37 [95% CI 1.03, 1.82]). Conclusions/interpretation: This study in individuals with type 2 diabetes and diabetic kidney disease suggests that the beneficial effects of angiotensin receptor blockers are similar in male and female participants for the kidney outcome but not for the cardiovascular outcome. More attention to sex differences in angiotensin receptor blockers’ efficacy and underlying mechanisms of differences in response is needed. Trial registration: ClinialTrials.gov
Keywords
Angiotensin receptor blockers, Cardiovascular outcome, Diabetic kidney disease, Kidney outcome, Renin–angiotensin system, Sex differences, Taverne, Internal Medicine, Endocrinology, Diabetes and Metabolism
Citation
de Vries, S T, Pena, M J, Tye, S C, Peters, S A E, van Raalte, D H, Arnott, C, Voors, A A, Mol, P G M, Denig, P & Heerspink, H J L 2025, 'Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease : post hoc analyses of the RENAAL and IDNT trials', Diabetologia, vol. 68, no. 3, pp. 507–515. https://doi.org/10.1007/s00125-024-06325-y